These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29520012)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.
    Bennett CF; Krainer AR; Cleveland DW
    Annu Rev Neurosci; 2019 Jul; 42():385-406. PubMed ID: 31283897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense oligonucleotides for therapeutic interventions in neuromuscular diseases.
    Danos O
    Hum Gene Ther; 2013 May; 24(5):470-1. PubMed ID: 23675648
    [No Abstract]   [Full Text] [Related]  

  • 25. Gene-targeted therapies for the central nervous system.
    Miller TM; Smith RA; Kordasiewicz H; Kaspar BK
    Arch Neurol; 2008 Apr; 65(4):447-51. PubMed ID: 18268183
    [No Abstract]   [Full Text] [Related]  

  • 26. Overview on AON design.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells.
    Sewing S; Gubler M; Gérard R; Avignon B; Mueller Y; Braendli-Baiocco A; Odin M; Moisan A
    Mol Ther Nucleic Acids; 2019 Mar; 14():67-79. PubMed ID: 30583097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of Antisense Oligonucleotides to the Mouse Retina.
    Garanto A
    Methods Mol Biol; 2022; 2434():321-332. PubMed ID: 35213028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in therapeutic antisense applications for neuromuscular disorders.
    Aartsma-Rus A; van Ommen GJ
    Eur J Hum Genet; 2010 Feb; 18(2):146-53. PubMed ID: 19809477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on RNA-targeting therapies for neuromuscular disorders.
    Jirka S; Aartsma-Rus A
    Curr Opin Neurol; 2015 Oct; 28(5):515-21. PubMed ID: 26280937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
    Pramono ZA; Wee KB; Wang JL; Chen YJ; Xiong QB; Lai PS; Yee WC
    Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model.
    Relizani K; Griffith G; Echevarría L; Zarrouki F; Facchinetti P; Vaillend C; Leumann C; Garcia L; Goyenvalle A
    Mol Ther Nucleic Acids; 2017 Sep; 8():144-157. PubMed ID: 28918017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
    Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
    Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1828():381-394. PubMed ID: 30171555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
    Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
    Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
    Bizot F; Vulin A; Goyenvalle A
    Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.